Nintedanib—Efficacy, Safety and Practical Aspects of Treatment for Patients with Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a rare disease with progressive course and a very unfavourable prognosis. Antifibrotic drugs are a chance to reduce the rate of disease progression and extend the life of IPF patients. One of these drugs is nintedanib, an oral tyrosine kinase inhibitor. In the following article, the reader will find a summary of current knowledge on the efficacy and safety of nintedanib treatment of IPF patients. This study uses data from pivotal studies and experience from everyday clinical practice indicating a wide range of possible applications of the drug in IPF patients.